BridgeBio Pharma Inc (NASDAQ: BBIO) on Tuesday, soared 6.00% from the previous trading day, before settling in for the closing price of $62.81. Within the past 52 weeks, BBIO’s price has moved between $21.72 and $69.48.
Annual sales at Healthcare sector company slipped by -3.04% over the past five years. The company achieved an average annual earnings per share of -21.35%. With a float of $163.83 million, this company’s outstanding shares have now reached $192.63 million.
BridgeBio Pharma Inc (BBIO) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BridgeBio Pharma Inc is 14.99%, while institutional ownership is 88.77%. The most recent insider transaction that took place on Nov 06 ’25, was worth 2,526,117. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $63.15, taking the stock ownership to the 815,686 shares. Before that another transaction happened on Nov 07 ’25, when Company’s Chief Executive Officer sold 40,000 for $61.42, making the entire transaction worth $2,456,994. This insider now owns 795,686 shares in total.
BridgeBio Pharma Inc (BBIO) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.37 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.09) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.35% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
BridgeBio Pharma Inc (BBIO) is currently performing well based on its current performance indicators. A quick ratio of 3.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -1.70 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 2.31 million, a negative change from its year-to-date volume of 2.85 million. As of the previous 9 days, the stock’s Stochastic %D was 43.16%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 89.71%, which indicates a significant increase from 82.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.23 in the past 14 days, which was higher than the 1.94 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $55.67, while its 200-day Moving Average is $43.09. Nevertheless, the first resistance level for the watch stands at $68.18 in the near term. At $69.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $72.84. If the price goes on to break the first support level at $63.52, it is likely to go to the next support level at $60.46. Assuming the price breaks the second support level, the third support level stands at $58.86.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
Market capitalization of the company is 12.83 billion based on 192,709K outstanding shares. Right now, sales total 221,900 K and income totals -535,760 K. The company made 120,700 K in profit during its latest quarter, and -182,740 K in sales during its previous quarter.
